Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 4/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16150279 | 0.91 | CCNB2 (0.37) | TBXA2RPPARG | |
| SCHEMBL856144 | 0.75 | TBXA2R (0.39) | TBXA2RPPARGALOX5AP | |
| SCHEMBL482970 | 0.74 | BACE1 (0.35) | TBXA2R | |
| SCHEMBL31144615 | 0.72 | HTR6 (0.44) | TBXA2RPPARGHDAC6 | |
| SCHEMBL3756850 | 0.72 | CCNB2 (0.41) | — | |
| SCHEMBL4442924 | 0.72 | ALOX5AP (0.41) | PPARGALOX5APHDAC6 | |
| SCHEMBL1300216 | 0.71 | CNR2 (0.38) | TBXA2R | |
| SCHEMBL10173079 | 0.69 | CCNB2 (0.39) | — | |
| SCHEMBL481590 | 0.68 | BACE1 (0.41) | — | |
| SCHEMBL4527113 | 0.68 | CCNB2 (0.38) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370933-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370933-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | TBXA2R 3105/4885PPARG 737/4885ALOX5AP 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.